Close Menu

prostate cancer

The work is being funded with $26.5 million from the 21st Century Cures Cancer Moonshot Initiative.

Researchers characterized genetic, transcriptomic, and clinical features in advanced prostate cancers that emerged from treatment.

Under the new collaboration, Predicine will use its GeneRADAR technology to aid Kintor in the development and advancement of novel drugs.

Results support the ability of the test to not only identify hormonal therapy non-responders, but to predict their improved survival on chemotherapy.

Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.

Proceeds will be used to support studies for regulatory submissions to the FDA for the company's metastatic breast cancer test, among other things.

Cigna is the first national private payor to provider coverage for the Decipher tests, which provide a genomic assessment of tumor aggressiveness.

The researchers used 10X Genomics' linked-read genome sequencing approach to home in on rearrangements that affect the androgen receptor locus and its enhancer.

Using data for more than 140,000 individuals, researchers narrowed in on 63 new prostate cancer-associated loci and established a polygenic score linked to enhanced risk.

A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.